Full Press Release Details
Lifesciences Announces 1-for-25 Reverse Stock Split
as of Commencement of Trading on May 9, 2025
CA - May 7, 2025 - ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led
weight loss and metabolic health solutions company, today announced that its Board of Directors has declared a 1-for-25 reverse stock
split of the company's common stock, which will be effective for trading purposes upon the commencement of trading on May 9,
2025. At that time, each 25 shares of issued and outstanding common stock and equivalents will be converted into one share of common stock.
As a result of the reverse stock split, proportional adjustments will be made to the number of shares of common stock issuable upon exercise
or conversion, and the per share exercise or conversion price of the company's outstanding warrants, stock options and convertible
preferred stock, in each case in accordance with their terms. Any fractional shares of common stock resulting from the reverse stock split
will be rounded up to the nearest whole share. The number of authorized shares of common stock and preferred stock under the company's
certificate of incorporation will not be reduced in connection with the reverse stock split.
stock split was approved by ReShape Lifesciences' stockholders at the company's special meeting of stockholders held
on April 1, 2025. ReShape Lifesciences stockholders will receive instructions from the company's transfer agent, Equiniti Trust
Company, LLC, as to procedures for exchanging existing stock certificates for new certificates or book-entry shares. The new CUSIP number
for the company's common stock following the reverse stock split will be 76090R408.
ReShape Lifesciences Inc.
Lifesciences is America's premier weight loss and metabolic health-solutions company, offering an integrated
portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band System
provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such
as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN ) system utilizes
a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The
Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide
long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.
ReShape Lifesciences Investor
President and Chief Executive
Investor Relations Contact:
Rx Communications Group